ArticleScientific reports2017

KRAS mutation and primary tumor location do not affect efficacy of bevacizumab-containing chemotherapy in stagae IV colorectal cancer patients.

De-Cong Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.